Liposomal Bupivacaine Market Analysis By Type (20ml, 10ml), By Application (Veterinary, Human) and Regional Insights and Forecast to 2033

•   
•   
  

  Request a Free sample to learn more about this report

    

LIPOSOMAL BUPIVACAINE MARKET OVERVIEW

The global liposomal bupivacaine market size was valued at USD 0.69 billion in 2024 and will reach USD 1.14 billion by 2033, reflecting a CAGR of 5.2% during the forecast period 2025-2033.

After surgery, especially after medical procedures such as haemorrhoids and bunionectomy, patients are in dire need of pain relief medication or treatment which is also long-lasting in nature. In such instances, local anaesthetic liposomal bupivacaine is a must since it allows for pain management options which are not opioid based, and therefore less risky and more viable for patients.

The liposomal bupivacaine market growth in recent years has been drastic, since this substance is very effective lowers opioid dependence for pain management, and therefore the market for this medication has grown substantially.

KEY FINDINGS

COVID-19 IMPACT

Market Growth Restrained due to Production Disruptions

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to market’s growth and demand returning to pre-pandemic levels.

Redistributing budgets for healthcare resources and reducing elective procedures like pain management treatments during the pandemic were the main reasons for decline in both demand and sales. But as soon as healthcare systems made the required adjustments according to the pandemic situation, industries got back to business as usual and the liposomal bupivacaine market growth started to rebound.

LATEST TRENDS

Rising Preference for Pain Management Solutions without using Opioids

Since customers' preference for non-opioid analgesics is growing, this proves to be good news for the liposomal bupivacaine market growth. The effective pain relief and lower risk of addiction that patients and healthcare providers want is present in this alternative pain management method, thanks to the extended-release formulation of liposomal bupivacaine that helps elevate patients' pain in a sustainable and effective way.

• According to the U.S. Food and Drug Administration (FDA), over 20 million surgical procedures were performed annually in the U.S. as of 2023, significantly boosting demand for non-opioid analgesics like liposomal bupivacaine for post-surgical pain management.

• As per the American Society of Anesthesiologists (ASA), approximately 60% of hospitals in the U.S. implemented enhanced recovery protocols by 2024, integrating liposomal bupivacaine as part of opioid-sparing strategies.

•   
•   
  

  Request a Free sample to learn more about this report

    

LIPOSOMAL BUPIVACAINE MARKET SEGMENTATION

By Type

• 20ml: When longer pain relief is needed during more involved surgical procedures, the 20 ml liposomal bupivacaine formulation is frequently utilised. Because it can produce prolonged analgesia, this dosage form is preferred in both veterinary and human applications as it lessens the need for additional pain relief interventions.

• 10ml: For simpler or less invasive procedures, the 10 ml formulation is frequently utilised. It works well for outpatient surgeries and minor procedures where a high volume of medication is not required because it effectively manages pain with a lower volume.

By Application

• Veterinary: The animals which need liposomal bupivacaine happen during instances where surgery needs to be performed, or post-operation care needs to be administered. Animals undergoing surgery can be made to feel less pain by administering this substance, and its capacity to relieve pain for longer periods of time is an added advantage, so that post-operative care, recovery results, and need for opioids or other painkillers can be tackled in animals.

• Human: In humans, liposomal bupivacaine is mainly used for pain relief after procedures or operations are carried out, pertaining to issues such as haemorrhoids and bunionectomy. It is adopted and applied in a number of surgical procedures, and ultimately helps in improving patient comfort and recovery after operations.

DRIVING FACTORS

Growth of Advanced Anaesthetics and their Adoption

The main reason for the liposomal bupivacaine market's growth is the increased usage of anaesthetics that help by slowly releasing pain reducing substances in a patient’s body. They also decrease negative after effects in such individuals so that they no longer require very frequent doses of the substance, and in the big picture they really enhance the comfort level which medical institutes are able to provide.

• According to the U.S. Centers for Disease Control and Prevention (CDC), opioid overdose deaths exceeded 81,000 cases in 2022, prompting national policies encouraging hospitals to adopt alternatives like liposomal bupivacaine.

• As per data published by the Agency for Healthcare Research and Quality (AHRQ), outpatient surgeries accounted for 65% of all surgeries in the U.S. by 2023, driving adoption of long-acting anesthetics such as liposomal bupivacaine for same-day discharges.

Rising Awareness of Opioid Alternatives leading to Market Growth

The growing use of liposomal bupivacaine is because of the function it serves in medical procedures and applications where it acts as a post-operative pain management strategy. This is attributed to the increased awareness of opioid addiction in patients who did not have any alternate substances to relieve their pain before the invention of high-quality liposomal bupivacaine. That is the reason why the growth of these better alternatives to dangerous opioid containing substances has been substantial in the global market, and has also made it so that both patients and medical facilities or institutions almost always choose to use these painkillers for patient care.

RESTRAINING FACTORS

Market Growth Deterred due to High Cost of Anaesthetics

One major factor that causes hindrance in the growth of global markets is the high cost associated with the liposomal bupivacaine market as compared to any alternate traditional anaesthetics. Its sophisticated manufacturing and formulation processes are the reason for its exorbitant price, which may limit its adoption across industries because of less accessibility in healthcare settings where financial constraints are present.

• According to a pricing comparison study published in the Journal of Managed Care & Specialty Pharmacy (2023), liposomal bupivacaine can cost up to 20 times more than traditional bupivacaine, limiting its usage in cost-sensitive healthcare settings.

• Based on data from the European Medicines Agency (EMA), fewer than 40% of EU countries had standard reimbursement policies for liposomal formulations as of 2023, restricting broader clinical uptake.

•   
•   
  Request a Free sample to learn more about this report

    

LIPOSOMAL BUPIVACAINE MARKET REGIONAL INSIGHTS

North America To Dominate The Market Owing To Strong Healthcare Infrastructure

The global liposomal bupivacaine market is segmented into North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.

North America is the geographical region which is expected to drive market expansion due to its sophisticated healthcare system and high rate of adoption of cutting-edge medical technologies. Due to significant industry players, a sophisticated healthcare system, and growing demand for effective pain management treatments, North America is predicted to lead the liposomal bupivacaine market share worldwide.

KEY INDUSTRY PLAYERS

Key Industry Players Shaping the Market through Research and Development

Leading companies in the liposomal bupivacaine market are propelling expansion with creative thinking and calculated moves. Companies are allocating their budgets specifically to spend more money on efforts aimed at research and development so that they can overall improve the formulas for their liposomal bupivacaine delivery. Expanding the market is further aided by strategic partnerships with medical facilities and institutions.

• Pacira Pharmaceuticals, Inc.: According to company-reported clinical data (Pacira Annual Report 2023), their flagship product, EXPAREL® (liposomal bupivacaine), has been administered in over 12 million patients globally, making it one of the most extensively used non-opioid analgesics in surgery.

List of Top Liposomal Bupivacaine Companies

• Pacira Pharmaceuticals (U.S.)

INDUSTRIAL DEVELOPMENT

July, 2024: With the goal of improving the liposomal bupivacaine formulation to expand their product lines, pharmaceutical companies held extensive research and development operations, and is holding clinical trials to get the same approved. This new formulation guarantees that the safety and efficacy of liposomal bupivacaine will now be increased, so that the pain management global systems can progress and help in securing market positions of key players.

REPORT COVERAGE

The study offers a thorough examination of the global liposomal bupivacaine market, paying close attention to its size, segmentation, and geographical dynamics. By highlighting the various factors supporting and obstructing market growth, it offers a thorough understanding of the dynamics influencing market trends. By combining historical data with future projections to provide a thorough overview of the market landscape, the report guarantees that readers will gain insightful understanding of the evolving conditions of the market.

The report also highlights how the market dynamics are affected by factors such as the competitive landscape, significant industry players and their strategic initiatives that end up changing the market scenario in the long run. The writeup also includes an extensive forecast between the years of 2023 and 2029 and how the anticipated developments and advancements in the industry so that stakeholders can be assisted while forming well-informed decisions regarding their strategic planning.